INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.490
+0.040 (2.76%)
At close: Apr 20, 2026, 4:00 PM EDT
1.459
-0.031 (-2.08%)
After-hours: Apr 20, 2026, 7:16 PM EDT
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
$2,381
Profits / Employee
-$2,187,286
Market Cap
39.61M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| NextCure | 40 |
| Palatin Technologies | 29 |
| Daré Bioscience | 24 |
| Veru Inc. | 20 |
| Outlook Therapeutics | 17 |
| Sensei Biotherapeutics | 15 |
INMB News
- 21 days ago - INmune Bio Inc. Announces 2025 Results and Provides Business Update - GlobeNewsWire
- 27 days ago - INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - GlobeNewsWire
- 2 months ago - INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar - GlobeNewsWire
- 2 months ago - INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - GlobeNewsWire
- 2 months ago - INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB - GlobeNewsWire
- 2 months ago - INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - GlobeNewsWire
- 4 months ago - Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform - GlobeNewsWire
- 5 months ago - INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients - GlobeNewsWire